{"paper_id":"857e3639-d87a-4d7f-a7a0-73f9236b305a","body_text":"1. Dumanovskaya MR, Chernukha GE, Tabeeva GI, et al. Endometrial hyperplasia: search for optimal solutions and strategies. Akusherstvo i Ginekologiia. 2021;4:23-31. DOI: 10.18565/aig.2021.4.23-31\n2. Zakrzewski PK. Canonical TGFβ signaling and its contribution to endometrial cancer development and progression – underestimated target of anticancer strategies. J Clin Med. 2021;10(17):3900. DOI: 10.3390/jcm10173900\n3. Ruiz-Mitjana A, Navaridas R, Vidal-Sabanes M, et al. Lack of extracellular matrix switches TGF-β induced apoptosis of endometrial cells to epithelial to mesenchymal transition. Sci Rep. 2022;12(1):14821. DOI: 10.1038/s41598-022-18976-1\n4. Chen PY, Qin L, Simons M. TGFβ signaling pathways in human health and disease. Front Mol Biosci. 2023;10:1113061. DOI: 10.3389/fmolb.2023.1113061\n5. Zhao H, Wei J, Sun J. Roles of TGF-β signaling pathway in tumor microenvironment and cancer therapy. Int Immunopharmacol. 2020;89:107101. DOI: 10.1016/j.intimp.2020.107101\n6. Kriseman M, Monsivais D, Agno J, et al. Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer. Proc Natl Acad Sci U S A. 2019;116(9):3873-82. DOI: 10.1073/pnas.1806862116\n7. Lv M, Chen P, Bai M, et al. Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers (Basel). 2022;14(24):6210. DOI: 10.3390/cancers14246210\n8. Fedotcheva TA. Clinical use of progestins and their mechanisms of action: present and future (review). Sovremennye Tekhnologii v Meditsine. 2021;13(1):93-108. DOI: 10.17691/stm2021.13.1.11\n9. Badlaeva AS, Vardanyan MA, Chekeneva NA, et al. Immunohistochemical evaluation of epithelial-mesenchymal transition markers in various forms of endometriosis. Sovremennye Problemy Nauki i Obrazovaniya. 2025;1. DOI: 10.17513/spno.33810\n10. Cizkova K, Foltynkova T, Gachechiladze M, et al. Comparative analysis of immunohistochemical staining intensity determined by light microscopy, ImageJ and QuPath in placental Hofbauer cells. Acta Histochem Cytochem. 2021;54(1):21-9. DOI: 10.1267/ahc.20-00032\n11. Omelchenko VP, Demidova AA. Informatics, medical informatics, statistics. Moscow: GEOTAR-Media; 2021. 608 p. DOI: 10.33029/9704-5921-8-MIS-2021-1-608\n12. Rodriguez GC, Rimel BJ, Watkin W, et al. Progestin treatment induces apoptosis and modulates transforming growth factor-? in the uterine endometrium. Cancer Epidemiol Biomarkers Prev. 2008;17(3):578-84. DOI: 10.1158/1055-9965\n13.Delbandi AA, Mahmoudi M, Shervin A, et al. Evaluation of apoptosis and angiogenesis in ectopic and eutopic stromal cells of patients with endometriosis compared to non-endometriotic controls. BMC Womens Health. 2020;20(1):3. DOI: 10.1186/s12905-019-0865-4\n14. Wang F, Qualls AE, Marques-Fernandez L, et al. Biology and pathology of the uterine microenvironment and its natural killer cells. Cell Mol Immunol. 2021;18:2101-13. DOI: 10.1038/s41423-021-00739-z\n15. Chemerinski A, Garcia de Paredes J, Blackledge K, et al. Mechanisms of endometrial aging: lessons from natural conceptions and assisted reproductive technology cycles. Front Physiol. 2024;28(15):1332946. DOI: 10.3389/fphys.2024.1332946\n16. Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020;223(1):103. DOI: 10.1016/j.ajog.2019.12.273\n17. Yu HF, Yang ZQ, Xu MY, et al. Yap is essential for uterine decidualization through Rrm2/GSH/ROS pathway in response to Bmp2. Int J Biol Sci. 2022;18(6):2261-76. DOI: 10.7150/ijbs.67756\n18. Yang B, Hu M, Fu Y, et al. LASS2 mediates Nrf2-driven progestin resistance in endometrial cancer. Am J Transl Res. 2021;15(13):1280-9.\n19. Reis FM, Ribeiro MF, Maia AL, et al. Regulation of human endometrial transforming growth factor ?1 and ?3 isoforms through menstrual cycle and medroxyprogesterone acetate treatment. Histol Histopathol. 2002;17:739-45. DOI: 10.14670/HH-17.739\n20. Kumari A, Shonibare Z, Monavarian M, et al. TGF? signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021;38(2):139-61. DOI: 10.1007/s10585-021-10077-z\n21. Zubrzycka A, Migdalska-Sek M, Jedrzejczyk S, et al. The expression of TGF-?1, SMAD3, ILK and miRNA-21 in the ectopic and eutopic endometrium of women with endometriosis. Int J Mol Sci. 2023;24(3):2453. DOI: 10.3390/ijms24032453\n22. Kriseman ML, Tang S, Liao Z, et al. SMAD2/3 signaling in the uterine epithelium controls endometrial cell homeostasis and regeneration. Commun Biol. 2023;6(1):261. DOI: 10.1038/s42003-023-04619-2\n23. Kriseman M, Monsivais D, Agno J, et al. Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer. Proc Natl Acad Sci U S A. 2019;116(9):3873-82. DOI: 10.1073/pnas.1806862116\n24. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-6. PMID: 2081237.\n25. Clinical guidelines. Endometrial hyperplasia. Moscow: Ministry of Health of the Russian Federation; 2023. 56 p. (In Russ).","source_license":"CC0","license_restricted":false}